Bioline RX Ltd (NASDAQ:BLRX) reports its financial results for the third quarter ended September 30, 2016. Highlights and achievements during third quarter of 2016 …
Bioline RX Ltd (NASDAQ:BLRX) announced that it has signed an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of …
Bioline RX Ltd (NASDAQ:BLRX) disclosed positive Phase 2a correlative data, as well as detailed mechanism-of-action data, for BL-8040, the Company’s leading oncology platform, that …
Bioline RX Ltd (NASDAQ:BLRX) announced today that data on BL-8040, the Company’s leading oncology platform, have been accepted for presentations at the 58th …
Healthcare analysts chimed in on Bioline RX Ltd (NASDAQ:BLRX) and Endo International plc – Ordinary Shares (NASDAQ:ENDP), as both stocks are among the top performers today. The …
Bioline RX Ltd (NASDAQ:BLRX) investors are cheering the news that the company has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer …
Bioline RX Ltd (NASDAQ:BLRX) announced its corporate objectives at an ongoing investor breakfast meeting at theConvene Conference Center near Grand Central in New York …
Bioline RX Ltd (NASDAQ:BLRX) announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients …
Bioline RX Ltd (NASDAQ:BLRX) announced that the successful final results of BL-8040’s Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r …
Bioline RX Ltd (NASDAQ:BLRX) announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase …
